Moreover, CTLA-4 indirectly modulates immunosuppression in the tumor microenvironment (TME) by limiting CD4 + T cells' clonal expansion, which is essential for targeting malignant tumor cells through direct killing or enhancing cytotoxic T-cells and B-cells immune response [6, 46, 69, 102]. The gene discussed is CD4; the disease is neoplasm.